DMARDs for Rheumatoid Arthritis: A Meta-Analysis
- Researchers are conducting a network meta-analysis to assess the effectiveness and risks of various disease-modifying anti-rheumatic drugs (DMARDs) in treating adults with rheumatoid arthritis.
- The study also aims to rank these interventions based on their benefits and harms.
- One review will examine dmards as an initial therapy for rheumatoid arthritis.
Meta-Analysis to Evaluate DMARDs for Rheumatoid Arthritis Treatment
Updated June 2, 2025
Researchers are conducting a network meta-analysis to assess the effectiveness and risks of various disease-modifying anti-rheumatic drugs (DMARDs) in treating adults with rheumatoid arthritis. The primary goal is to compare DMARDs used as a first-line treatment and after conventional synthetic DMARDs or biologic or targeted synthetic DMARDs have proven ineffective.
The study also aims to rank these interventions based on their benefits and harms. The analysis will be divided into three separate Cochrane Reviews, each focusing on a specific patient population.
One review will examine dmards as an initial therapy for rheumatoid arthritis. A second will focus on dmards used after conventional synthetic DMARDs have failed. The third review will analyze DMARDs used after biologic or targeted synthetic therapies have been unsuccessful. This comprehensive approach seeks to provide a detailed comparison of DMARDs for rheumatoid arthritis treatment, informing clinical decisions and improving patient outcomes.
What’s next
The results of these meta-analyses will be published as three separate Cochrane Reviews, providing clinicians with evidence-based recommendations for selecting the most appropriate DMARD therapy for their patients.